Gain Therapeutics (GANX) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Gain Therapeutics (GANX) over the past year, gaining 2.0% versus a loss of 22.0%. Over five years, GANX leads with a -76.7% price change compared with -91.7% for PDSB. PDS Biotechnology is the larger company by market cap ($89.5 million vs $70.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | PDSB |
|---|---|---|
| Share price | $1.62 | $1.24 |
| Market cap | $70.70M | $89.51M |
| 1-day change | +0.31% | +21.08% |
| YTD return | -49.84% | +32.47% |
| 1-year return | -21.98% | +2.00% |
| 5-year return | -76.73% | -91.73% |
| EPS (TTM) | $-0.50 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $1.55 |
| 52-week low | $1.53 | $0.195 |
| Distance from 52-week high | -62.67% | -20.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +344.44% | +304.86% |
| Average volume | 493.98K | 23.24M |
| Shares outstanding | 43.64M | 72.47M |
| Employees | 20 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed GANX by 24.0 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
GANX vs PDSB FAQ
Which is bigger, Gain Therapeutics or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $89.51M compared with $70.70M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, GANX or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -21.98% for GANX (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.